Skip to main content
OpenTrials
Completed

NCT Number: NCT02344043

Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness

Purpose of the Study Critical illness requiring life support affects over 150 000 people in Ontario every year. With aggressive support, the number of people who die from critical illness is decreasing. However, people who survive often have neurological problems. These neurological problems often include difficulties with memory, concentration, and attention. These problems are associated with poor quality of life among survivors of critical illness. The aim of this study is to identify the factors that contribute to these neurological deficits. Specifically, the investigators are testing whether changes in oxygen delivery to the brain during critical illness are related to both short- and long-term neurological complications.

Procedures involved in the Research When patients are diagnosed with a critical illness such as shock or respiratory failure, they are treated with intravenous fluids, medications to raise their blood pressure, and can be placed on a ventilator to assist with their breathing. They are observed in an intensive care unit (ICU). This research protocol does NOT interfere with the normal treatment of patients with critical illness. The procedure involved in this research protocol requires the placement of two stickers to either side of the patient's forehead, and information about oxygen delivery to the brain will be recorded. When the patient has recovered from the critical illness, they will be asked to perform several neurological tests. Some of these tests will be done with a pencil and paper, while others will use a robotic device to test arm movements, reaction time, and concentration.

Potential Harms, Risks or Discomforts:

This research study involves the placement of a sticker sensor to either side of the forehead. Rarely, patients may develop a rash to these electrodes. The investigators monitor patients very carefully for rashes, and if a rash is to occur, the sticker sensor will be removed. With regards to the neurological testing, rarely patients can have some mild muscle stiffness after moving their arms in the robot. The investigators do not expect any other further harms, risks, or discomforts.

Completed

Looking for future studies?

Notify Me

Key information

About this study

A detailed protocol is currently under review for funding at Physician Services Incorporated, and can be included pending decision.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Critically ill patients defined as having either:
  • Respiratory failure: Defined as invasive mechanical ventilation for a predicted duration of >24 hours, or:
  • Shock: Defined as being on one of the following agents:
  • norepinephrine (>5 mcg/min) IV
  • epinephrine (at any dose)
  • vasopressin (in combination with another pressor)
  • milrinone (in combination with another pressor)

Exclusion criteria

  • expected survival <24 hours
  • history of cognitive dysfunction
  • unable to participate in follow up testing

Treatment and study plan

Near infrared spectroscopy

Device

This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation

Primary outcomes

  1. Delirium

    Time frame: Proportion of ICU stay spent delirious. The average ICU stay is 7 days at our institution, however, some patients may stay much longer. We will perform delirium screening to a maximum of 30 days after ICU admission.

    The CAM-ICU and ICDSC are used to screen for delirium in critically ill patients. On the basis of these two validated screening tools, patients will be categorized as either comatose, delirious, or intact. The percentage of ICU stay that the participant spends delirious is the primary outcome measure.

Secondary outcomes

  1. Neurocognitive performance on KINARM tasks

    Time frame: 3 and 12 months

    The KINARM is a robotic device that provides quantitative metrics of the neurocognitive control of upper arm movements.

  2. Neurocognitive performance on the RBANS

    Time frame: 3 and 12 months

    The RBANS is the repeatable battery for the assessment of neuropsychological status

  3. Correlation between brain tissue oxygenation and physiological parameters

    Time frame: First 24 hours of admission

    We will use correlation coefficients to describe the relationship between brain tissue oxygenation and physiological parameters recorded during the first 24 hours of critical illness.

Sponsors and collaborators

Lead sponsor

Queen's University

Other

Registry information

Acronym: CONFOCAL

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Jan 22, 2015
Registry last updated
Nov 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.